rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Willard H. Dere

Director

Company insider

Files Form 4 as: Director, Seres Therapeutics; Director, Metagenomi Therapeutics; Director, BioMarin Pharmaceutical; Director, Mersana Therapeutics; Director, Radius Health; Director, Ocera Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
103
Buys
0
Sells
3
Bought
$0
Sold
$619K
Companies
6
Companies where not an officer
6
First trade
1 Nov 2014
Last trade
8 Jul 2026
Last filed
10 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
MCRB Seres TherapeuticsDirector · Biotechnology · last 8 Jul 20260 buys · 0 sells
MGX Metagenomi TherapeuticsDirector · Biotechnology · last 9 Jun 20260 buys · 0 sells
BMRN BioMarin PharmaceuticalDirector · Biotechnology · last 2 Jun 20260 buys · 1 sell
Mersana TherapeuticsDirector · Biotechnology · last 6 Jan 20260 buys · 0 sells
Radius HealthDirector · last 15 Aug 20220 buys · 2 sells
Ocera TherapeuticsDirector · last 11 Dec 20170 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
8 Jul 2026filed 10 Jul 2026MCRB Seres Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—6,500 at $0.00filing
8 Jul 2026filed 10 Jul 2026MCRB Seres Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—6,500 at $0.00filing
9 Jun 2026filed 11 Jun 2026MGX Metagenomi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,000 at $0.00filing
9 Jun 2026filed 11 Jun 2026MGX Metagenomi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,000 at $0.00filing
2 Jun 2026filed 4 Jun 2026BMRN BioMarin PharmaceuticalBiotechnologySEC FORM 4 Code A—7,490 at $0.00filing
2 Jun 2026filed 4 Jun 2026BMRN BioMarin PharmaceuticalBiotechnologySEC FORM 4 Code A—7,490 at $0.00filing
6 Jan 2026filed 6 Jan 2026Mersana TherapeuticsBiotechnologySEC FORM 4 Code U—1,567filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—513filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,800filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—734filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—2,200filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—2,460filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—800filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—2,460filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—800filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—544filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—1,000filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—450filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—368filing
6 Jan 2026filed 6 Jan 2026Mersana Therapeuticsoption or derivativeSEC FORM 4 Code D—125filing

Sectors

Health Care1
Not placed2

Buys in green, sells in red, by the company’s sector.

Related people

Gregory R. FribergEVP, Chief R&D Officer · EVP, Chief R&D Officer at Biomarin Pharmaceutical, filing Form 4 there in the last year
Robert M. PlengeDirector · Director at Biomarin Pharmaceutical, filing Form 4 there in the last year
Laurence ReidDirector · Director at Metagenomi Therapeutics, filing Form 4 there in the last year
Pamela WapnickChief Financial Officer · Chief Financial Officer at Metagenomi, filing Form 4 there in the last year
Matthew WeinOfficer · Officer at Metagenomi, filing Form 4 there in the last year
George Eric DavisEVP, Chief Legal Officer · Also traded BMRN in the last 90 days